Clinigma^® brings clarity and value to pharmaceutical companies by being their trial patients’ structured voice and strives to be the preferred solution for pharmaceutical companies on interviewing patients in clinical trials.

Clinigma^® strongly believes in the necessity of providing outstanding services and products consistently while being attentive to potential improvements throughout all aspects of its processes in order to meet the changing requirements and expectations from customers and regulatory authorities.

The Clinigma^® Quality Policy is based on the following principles and commitments:

CLINIGMA^® Management and employees are committed to assisting pharmaceutical companies to design their clinical development projects with a patient-focused approach and meet requirements and recommendations from competent authorities with regards to patient centricity in clinical studies.

CLINIGMA^® Management and employees are committed to continually developing and adjusting the methodology of establishing content validity to improve the data capture and resulting reports applied by pharmaceutical companies as part of their marketing authorization process.

CLINIGMA^® Management is committed to develop and maintain a robust and highly secure IT solution to support capturing data according to good IT practices and GDPR consent requirements.

CLINIGMA^® Management and employees are committed to consistently providing state-of-the-art qualitative analysis reports based on patient-experience data associated with clinical studies sponsored by pharmaceutical companies.

CLINIGMA^® Management and employees are committed to continuously reviewing and implementing external and internal requirements relevant for the development of the processes applied in the investigation, collection, management, analysis, storing and reporting of the patient-experience data.

CLINIGMA^® Management and employees are committed to continuously improving competencies relevant for the development processes leading to the final patient-experience data reports applied by the pharmaceutical companies.

CLINIGMA^® Management and employees are committed to ensuring that the experience of the interviewees is continuously under evaluation to establish opportunities for improvements of the developmental, empirical, and logistical processes.

CLINIGMA^® Management and employees are committed to evaluate the customers’ perception of the entire process leading up to and including the final patient-experience data report.